Veru Inc is trading at $3.94 (6.9% down) as the stock undergoes normalization and profit-taking following an 88% jump driven by its new clinical supply agreement with Novo Nordisk.
- The recent surge was fueled by excitement over the supply deal for the PLATEAU Phase 2b obesity trial, which provides strategic optionality for the company.
- Despite the clinical progress, the agreement includes no immediate cash infusion, leaving Veru Inc to face ongoing dilution and funding risks.